Technology Bundle ID
TAB-3602

Development and Use of O-linked beta-N-acetylglucosamine (O-GlcNAc) Transferase (OGT) Inhibitors for Multiple Conditions, Including Cancer

Applications
Linked ID
E-234-2018-0
Lead Inventors
Suzanne Walker (Harvard University)
Co-Inventors
Craig Thomas (NCATS)
Damien Duveau (NCATS)
Sara Martin Schwanger (Harvard University)
ICs
This technology includes the development and use of small molecules that inhibit O-linked beta-N-acetylglucosamine (O-GlcNAc) transferase (OGT) for a variety of pathologies, including Alzheimer's disease, cancer, cancer, diabetes, and neurodegenerative disorders the treatment of cancer and as a potential antiviral. OGT is a ubiquitous enzyme that catalyzes the transfer of N-acetylglucosamine (GlcNAc) to the serine or threonine residues of nuclear and cytoplasmic proteins. The addition of GlcNAc to proteins is a similar post-translational modification as phosphorylation and has been described to occur thousands of proteins.
Commercial Applications
Further work with O-linked beta-N-acetylglucosamine transferase (OGT) inhibitors will permit the further study of the biological role of OGT in cell homeostasis. Further clinical work could establish OGT inhibitors, alone or in combination with other agents, for the treatment of several disorders including cancer and as an antiviral.
Competitive Advantages
The series of O-linked beta-N-acetylglucosamine transferase (OGT) inhibitors described in this technology exhibit improved binding properties and OGT inhibition.

Request More Info

Licensing Contact: